Scratch CVTX off the list—just reported failure in the MERLIN TIMI-36 study: <A HREF="http://biz.yahoo.com/prnews/070306/nytu142.html?.v=88" target="_blank">http://biz.yahoo.com/prnews/070306/nytu142.html?.v=88</A>